Top Pharma CMO Holding Ground in This Competitive Market

Published: August 2024

Driven by the need for enhanced efficiency, traceability and cost-effectiveness, pharmaceutical contract manufacturing is undergoing technological advancements. Outsourcing manufacturing operations to CMOs and CDMOs entails the implementation of specialized solutions to optimize production workflows, ensure regulatory compliance, and maintain product quality standards.We analyzed over 420 pharmaceutical contract manufacturing companies that are engaged in offering small molecule contract manufacturing services. In this article, discover eight top pharma CMO companies and their capabilities in contract manufacturing market.

The landscape of pharmaceutical contract manufacturing is envisioned to be innovative and efficient. As technological advancements and market demands for novel therapeutics continue to evolve, CMOs are anticipated to navigate through the emerging trends, including personalized medicine and precision therapeutics, continuous manufacturing processes, supply chain optimization, digital health integration and many more. For instance, with a heightened emphasis on personalized therapies, and rapid drug development, CMOs are expected to invest in cutting-edge manufacturing technologies and flexible production processes. Additionally, the demand for sustainable and eco-friendly practices is likely to drive CMOs towards environment-friendly manufacturing methods. Furthermore, a focus on regulatory compliance and quality assurance will remain paramount, as the pharmaceutical landscape undergoes dynamic shifts.

Roots Analysis has conducted an exhaustive study on Pharmaceutical Contract Manufacturing Market featuring the current market landscape and future opportunity for the companies engaged in offering contract manufacturing services related to pharmaceutical contract manufacturing, over a span of 11 years.

Below, we have listed (in alphabetical order), the top eight Pharma CMO.

Aenova
Almac
Altasciences
Cambrex
Catalent
Corden Pharma
Curia (formerly AMRI)
Hovione

Top pharmaceutical contract manufacturing Companies

Interested in exploring all 420+ Pharma CMO and their recent initiatives?

Discover Below the Details on 8 Top Pharma CMO

Let us deep dive to understand the activity of the 8 top contract manufacturing companies in the Pharmaceutical Contract Manufacturing market. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

In 2023, Aenova Expanded its Solid Oral Dosage Production Capacity at the Tittmoning Site

1. Aenova

Aenova is a German CDMO that claims to be focused on the manufacturing of a wide range of products, including pharmaceutical products, medical devices, veterinary medicinal products, dietary supplements, and cosmetics and nutricosmetics. As per the firm’s website, it has established 15 production sites across North America and Europe to cater to the needs of its global clientele. It is worth highlighting that, in 2012, the company was acquired by BC Partners.

Aenova: Company Overview

Key Parameters	Description
Company Logo
Headquarters	Germany
Year of Establishment	2008
Number of Employees	1,001-5,000

In 2023, Aenova expanded both its capsule filling and tablet packaging capacity at its Tittmoning, Germany facility. They acquired a state-of-the-art IMA capsule filling machine. Also, the plan is to expand tablet packaging capacity by 1 billion tablets per year by 2025.

Further details on recent initiatives taken by Aenova and other pharma CMO have been provided in detail in the report.

In 2024, Almac Company Expanded its Commercial Manufacturing and Packaging as well as Peptide Production Capacity

2. Almac
Almac is an Italian contract development and manufacturing organization that claims to offer a wide range of services related to the discovery and development of biomarkers and APIs to pharmaceutical and biotechnology industries. It is worth mentioning that, as per the firm’s website, it has a strong global presence with its production facilities spread across Ireland, the UK, the US (California, North Carolina and Pennsylvania) and Asia-Pacific (Singapore and Japan).

Almac: Company Overview

Key Parameters	Description
Company Logo
Headquarters	Italy
Year of Establishment	1968
Number of Employees	5,001-10,000

In 2024, Almac completed the expansion of its two manufacturing, production and diagnostic facilities in Craigavon, Northern Ireland. One facility manufactures and packages sachet drug products and the other facility is dedicated to manufacturing the company’s peptide API.

Further details on recent initiatives taken by Almac and other pharma CMO have been provided in detail in the report.

Altasciences Acquired Calvert Laboratories, a Preclinical Contract Research Organization, in Order to Increase its Small Molecule Expertise and Expand Existing Capabilities

3. Altasciences

Altasciences is a US-based contract research, development and manufacturing organization that was established in 1992. It claims to operate as a one-stop-shop, offering a range of preclinical and clinical services, such as preclinical safety testing, bioanalysis, clinical monitoring, medical writing, biostatistics and data management, to its global clientele. The company further states to have developed various proprietary communication platforms, namely ATLAS and Tell us Once, in order to streamline the overall drug development process.

Altasciences: Company Details

Key Parameters	Description
Company Logo
Headquarters	Canada
Year of Establishment	1992
Number of Employees	1,001-5,000

In July 2022, Altasciences announced the expansion of its CDMO facility based in Philadelphia, US to increase its capacity and meet the ever-growing needs of its clients.

Further details on recent initiatives taken by Altasciences and other pharma CMO have been provided in detail in the report.

In 2023, Cambrex Expanded its Capacity at its Small Molecule API Manufacturing Facility in High Point, North Carolina

4. Cambrex

Cambrex is a privately held, US-based company that claims to be engaged in offering services related to the development and manufacturing of small molecules. It is worth mentioning that the firm offers end-to-end analytical solutions for drug substance and drug product manufacturing. With more than 35 years of experience, the company is a well-established contract development and manufacturing organization that caters to the needs of innovator and generic pharmaceutical companies based across the globe.

Cambrex: Company Overview

Key Parameters	Description
Company Logo
Headquarters	US
Year of Establishment	1981
Number of Employees	1,001-5,000

In January 2023, Cambrex acquired Snapdragon Chemistry, with an aim to expand its API development services. In October 2023, Cambrex announced completion of capacity expansion at its High Point, North Carolina facility. The $38 million expansion doubled the small molecule API manufacturing capacity.

Further details on recent initiatives taken by Cambrex and other pharma CMO have been provided in detail in the report.

Novo Nordisk to Acquire Catalent and Gain Hold of its Manufacturing Capacities

5. Catalent

Catalent is a US-based company that claims to have expertise in providing integrated services and manufacturing solutions to pharmaceutical and biotechnology industries. Further, it states to have considerable experience in the manufacturing of APIs and handling complex formulations. As per the firm’s website, it has manufactured more than 70 billion doses of products for over 1,000 customers, based across the world.

Catalent: Company Overview

Key Parameters	Description
Company Logo
Headquarters	US
Year of Establishment	2007
Number of Employees	10,001+

Further details on recent initiatives taken by Catalent and other pharma CMO have been provided in detail in the report.

Corden Pharma Announced the Expansion of its Peptide Manufacturing Capacity at its Facility Based in Colorado, US

6. Corden Pharma

Corden Pharma is a German contract development and manufacturing organization that was established in 2006. It claims to be focused on offering an array of services, ranging from research and development to product commercialization, through its cGMP production facilities based in the US and Europe. As per the firm’s website, it aims to operate as a one-stop-shop to cater to the needs of the pharmaceutical industry. The company’s capabilities span across four technology platforms, namely peptides, lipids and carbohydrates, injectables, and highly potent small molecules.

Corden Pharma: Company Overview

Key Parameters	Description
Company Logo
Headquarters	Switzerland
Year of Establishment	2006
Number of Employees	1,001-5,000

In 2024, Corden Pharma invested USD 981 million in order to bolster its ability to manufacture GLP-1 peptides in Europe and the US.

Further details on recent initiatives taken by Corden Pharma and other pharma CMO have been provided in detail in the report.

Curia, Providing Drug Discovery to Drug Substance Support for Small Molecules, Expanded its Foothold in Biologics Manufacturing with LakePharma Acquisition

7. Curia (formerly AMRI)

Curia is a US-based global contract development and manufacturing organization that was established in 1991. It is engaged in the discovery, development, and manufacturing of various pharmaceutical intermediates, including APIs and HPAPIs. It is worth highlighting that the firm has a standalone R&D division dedicated to the development of novel technologies to be leveraged in chemical development, discovery and analytical services. The firm offers these novel technologies either by licensing or by entering into co-development partnerships.

Curia: Company Overview

Key Parameters	Description
Company Logo
Headquarters	US
Year of Establishment	1991
Number of Employees	1,001-5,000

In July 2021, the company reinforced its positioning as a CDMO with name change (now Curia) and acquired the formulation and fill/finish company, Integrity Bio, and US based biologic CRO and CMO, LakePharma.

Further details on recent initiatives taken by AMRI and other pharma CMO have been provided in detail in the report.

Hovione is Getting on the Sustainable API Manufacturing Trend

8. Hovione

Hovione is a Portuguese contract development and manufacturing organization that claims to be engaged in the development and manufacturing of APIs and drug product intermediates. As per the firm’s website, it has a manufacturing capacity of more than 1,300 m³. Additionally, the company provides services for the development and manufacturing of innovative drugs, including highly potent compounds. It is worth mentioning that the firm is focused on the development of drug candidates for the treatment of a myriad of disease indications, including dermatological diseases, ophthalmological diseases and respiratory diseases.

Hovione: Company Overview

Key Parameters	Description
Company Logo
Headquarters	Portugal
Year of Establishment	1959
Number of Employees	1,001-5,000

In 2024, Hovione signed an agreement with Dragonfly Technologies in order to access its micellar technology for chemistry-in-water processes for API manufacturing technology offering.

Further details on recent initiatives taken by Hovione and other pharma CMO have been provided in detail in the report.

What About the Other Pharma CMO Around the World?

The above presentation features eight top Pharma CMO selected from a pool of over 420 players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.